Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Modulating the vascular behavior of metastatic breast cancer cells by curcumin treatment.

Palange AL, Di Mascolo D, Singh J, De Franceschi MS, Carallo C, Gnasso A, Decuzzi P.

Front Oncol. 2012 Nov 15;2:161. doi: 10.3389/fonc.2012.00161. eCollection 2012.

2.

Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells.

Palange AL, Di Mascolo D, Carallo C, Gnasso A, Decuzzi P.

Nanomedicine. 2014 Jul;10(5):991-1002. doi: 10.1016/j.nano.2014.02.004. Epub 2014 Feb 22.

5.

A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines.

Taurin S, Nimick M, Larsen L, Rosengren RJ.

Int J Oncol. 2016 Jan;48(1):385-98. doi: 10.3892/ijo.2015.3252. Epub 2015 Nov 19.

PMID:
26648459
6.

Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFkappaB, cyclinD and MMP-1 transcription.

Liu Q, Loo WT, Sze SC, Tong Y.

Phytomedicine. 2009 Oct;16(10):916-22. doi: 10.1016/j.phymed.2009.04.008. Epub 2009 Jun 12.

PMID:
19524420
8.

Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.

Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P.

Breast Cancer Res. 2005;7(4):R422-35. Epub 2005 Apr 4.

9.

MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.

Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, Sahin O, Wiemann S, Tschulena U.

Oncogene. 2012 Sep 13;31(37):4150-63. doi: 10.1038/onc.2011.571. Epub 2011 Dec 12.

PMID:
22158050
10.

A parallel-gradient microfluidic chamber for quantitative analysis of breast cancer cell chemotaxis.

Saadi W, Wang SJ, Lin F, Jeon NL.

Biomed Microdevices. 2006 Jun;8(2):109-18.

PMID:
16688570
11.

Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status.

Ray A, Nkhata KJ, Cleary MP.

Int J Oncol. 2007 Jun;30(6):1499-509.

PMID:
17487372
12.

Nitric Oxide-Releasing Aspirin Suppresses NF-κB Signaling in Estrogen Receptor Negative Breast Cancer Cells in Vitro and in Vivo.

Nath N, Chattopadhyay M, Rodes DB, Nazarenko A, Kodela R, Kashfi K.

Molecules. 2015 Jul 9;20(7):12481-99. doi: 10.3390/molecules200712481.

13.

Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.

Liu CY, Hung MH, Wang DS, Chu PY, Su JC, Teng TH, Huang CT, Chao TT, Wang CY, Shiau CW, Tseng LM, Chen KF.

Breast Cancer Res. 2014 Sep 17;16(5):431. doi: 10.1186/s13058-014-0431-9.

14.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

15.

The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.

Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, Chi CW, Chen DR.

Evid Based Complement Alternat Med. 2012;2012:486568. doi: 10.1155/2012/486568. Epub 2011 Jun 6.

16.

Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells.

Yoon MJ, Kim EH, Lim JH, Kwon TK, Choi KS.

Free Radic Biol Med. 2010 Mar 1;48(5):713-26. doi: 10.1016/j.freeradbiomed.2009.12.016. Epub 2009 Dec 28.

PMID:
20036734
17.

Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.

Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di GH, Jin W, Ou ZL, Shen ZZ, Shao ZM.

Breast Cancer Res. 2007;9(6):R76.

18.
19.

RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.

Yadav B, Taurin S, Larsen L, Rosengren RJ.

Int J Oncol. 2012 Nov;41(5):1723-32. doi: 10.3892/ijo.2012.1625. Epub 2012 Sep 11.

PMID:
22971638
20.

Estrogen receptor, growth factor receptor and protooncogene protein activities and possible signal transduction crosstalk in estrogen dependent and independent breast cancer cell lines.

Mohamood AS, Gyles P, Balan KV, Hollis VW, Eckberg WR, Asseffa A, Han Z, Wyche JH, Anderson WA.

J Submicrosc Cytol Pathol. 1997 Jan;29(1):1-17.

PMID:
9066137

Supplemental Content

Support Center